ijms-logo

Journal Browser

Journal Browser

New Insights in Cancer Drug Resistance Mechanisms and Targeted Therapies

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".

Deadline for manuscript submissions: closed (15 December 2021) | Viewed by 6330

Special Issue Editors


E-Mail Website
Guest Editor
Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400015 Cluj-Napoca, Romania
Interests: functional genomics; drug discovery; drug resitance; nutrigenomics
Special Issues, Collections and Topics in MDPI journals

E-Mail
Guest Editor
Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
Interests: cell toxicology; targeted therapies; exosomes and drug resistance

Special Issue Information

Dear Colleagues,

Drug resistance is the main obstacle to the successful treatment of cancer patients. Therefore, new approaches to study drug resistance in cancer as well as novel drugs and strategies to overcome drug resistance are required.

Particular attention will be given to research methods, such as computational approaches to predict drug response and drug interaction and laboratory-based research approaches. Such approaches will allow the identification of novel mechanistic insights that will lead to the discovery of novel biomarkers for drug response. Additional novel insights in epigenetic, mutational, or transcriptomic landscapes leading to the identification of novel therapeutic targets or biomarkers for patient classification or to monitor the response to therapy are also of interest for publication in this Special Issue.

Submissions on the following topics are invited:

  • computational modeling approaches to studying drug resistance
  • integrative bioinformatics analysis for omics studies with implications in biomarker discovery; data integration for early detection of tumors allowing the interception of cancer and adaptive monitoring during therapy
  • biological determinants of resistance, particular those related to the tumor microenvironment
  • novel drugs and improved pharmacological principles capable of counteracting drug resistance mechanisms

The Special Issue will include original and review papers presenting outstanding data on all aspects of drug resistance mechanisms in cancer.

Assoc. Pro Cornelia Braicu
Dr. Ioana Berindan-Neagoe
Dr. Ancuta Jurj
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer drug resistance
  • drug resistance mechanisms
  • resistance modulation
  • combined therapy
  • biomarkers for monitoring drug response

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

27 pages, 1422 KiB  
Review
State of the Art in the Current Management and Future Directions of Targeted Therapy for Differentiated Thyroid Cancer
by Horatiu Silaghi, Vera Lozovanu, Carmen Emanuela Georgescu, Cristina Pop, Bogdana Adriana Nasui, Adriana Florinela Cătoi and Cristina Alina Silaghi
Int. J. Mol. Sci. 2022, 23(7), 3470; https://doi.org/10.3390/ijms23073470 - 23 Mar 2022
Cited by 13 | Viewed by 5646
Abstract
Two-thirds of differentiated thyroid cancer (DTC) patients with distant metastases would be classified as radioactive iodine-refractory (RAIR-DTC), evolving into a poor outcome. Recent advances underlying DTC molecular mechanisms have shifted the therapy focus from the standard approach to targeting specific genetic dysregulations. Lenvatinib [...] Read more.
Two-thirds of differentiated thyroid cancer (DTC) patients with distant metastases would be classified as radioactive iodine-refractory (RAIR-DTC), evolving into a poor outcome. Recent advances underlying DTC molecular mechanisms have shifted the therapy focus from the standard approach to targeting specific genetic dysregulations. Lenvatinib and sorafenib are first-line, multitargeted tyrosine kinase inhibitors (TKIs) approved to treat advanced, progressive RAIR-DTC. However, other anti-angiogenic drugs, including single targeted TKIs, are currently being evaluated as alternative or salvage therapy after the failure of first-line TKIs. Combinatorial therapy of mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) signalling cascade inhibitors has become a highly advocated strategy to improve the low efficiency of the single agent treatment. Recent studies pointed out targetable alternative pathways to overcome the resistance to MAPK and PI3K pathways’ inhibitors. Because radioiodine resistance originates in DTC loss of differentiation, redifferentiation therapies are currently being explored for efficacy. The present review will summarize the conventional management of DTC, the first-line and alternative TKIs in RAIR-DTC, and the approaches that seek to overcome the resistance to MAPK and PI3K pathways’ inhibitors. We also aim to emphasize the latest achievements in the research of redifferentiation therapy, immunotherapy, and agents targeting gene rearrangements in advanced DTC. Full article
Show Figures

Figure 1

Back to TopTop